Carbonic Anhydrase IX/CA9 Antibody (66.4.C2 (PN-15)), Novus Biologicals™

Renal Cell Carcinoma (gp200)

0.2mg/mL

Monoclonal

Purified

RUO

PBS with 0.05% BSA. with 0.05% Sodium Azide

CD205LY-75, CLEC13BLy-75, C-type lectin domain family 13 member B, DEC-205CD205 antigen, GP200-MR6, lymphocyte antigen 75

LY75

IgG2b κ

Protein G purified

Recognizes a glycoprotein of ∼200kDa, identified as carbonic anhydrase IX (CAIX/gp200). Its epitope resides in the carbohydrate domain of gp200. It shows no significant cross-reactivity with other carbohydrate determinants, such as the Lewis blood group antigens, epithelial membrane antigen, HMFG, and AB blood group antigens. In normal kidney, gp200 is localized along the brush border of the pars convoluta and pars recta segments of the proximal tubule, as well as focally along the luminal surface of Bowman's capsule adjoining the outgoing proximal tubule. Reportedly, gp200 is expressed by 93% of primary and 84% of metastatic renal cell carcinomas. This MAb may be useful in the investigations of carcinomas of proximal nephrogenic differentiation especially those showing tubular differentiation.

66.4.C2 (PN-15)

Western Blot 0.5-1ug/ml, Flow Cytometry 0.5-1ug/million cells, ELISA 1-5ug/ml for coating, Immunocytochemistry/Immunofluorescence 1-2ug/ml, Immunoprecipitation 1-2ug/500ug protein lysate, Immunohistochemistry-Paraffin 0.5-1ug/ml, Immunohistochemistry-Frozen 0.5-1ug/ml

Unconjugated

Mouse

Dendritic Cell Markers, Ovarian Carcinoma Cell Markers, Renal Cell Carcinoma Cell Markers

Q16790

4065

Fresh, normal human renal cortical tissue homogenate was used as immunogen to generate the RCC antibody.

Primary

Store at 4C.